Exact Sciences Corporation (EXAS)
NASDAQ: EXAS · Real-Time Price · USD
101.64
-0.18 (-0.18%)
Dec 22, 2025, 10:17 AM EST - Market open
Exact Sciences Revenue
Exact Sciences had revenue of $850.74M in the quarter ending September 30, 2025, with 20.05% growth. This brings the company's revenue in the last twelve months to $3.08B, up 14.47% year-over-year. In the year 2024, Exact Sciences had annual revenue of $2.76B with 10.37% growth.
Revenue (ttm)
$3.08B
Revenue Growth
+14.47%
P/S Ratio
6.20
Revenue / Employee
$440,290
Employees
7,000
Market Cap
19.29B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.76B | 259.10M | 10.37% |
| Dec 31, 2023 | 2.50B | 415.49M | 19.93% |
| Dec 31, 2022 | 2.08B | 317.19M | 17.95% |
| Dec 31, 2021 | 1.77B | 275.70M | 18.49% |
| Dec 31, 2020 | 1.49B | 615.10M | 70.19% |
| Dec 31, 2019 | 876.29M | 421.83M | 92.82% |
| Dec 31, 2018 | 454.46M | 188.47M | 70.86% |
| Dec 31, 2017 | 265.99M | 166.61M | 167.66% |
| Dec 31, 2016 | 99.38M | 59.94M | 151.99% |
| Dec 31, 2015 | 39.44M | 37.93M | 2,522.14% |
| Dec 31, 2014 | 1.50M | -6.78M | -81.85% |
| Dec 31, 2013 | 8.29M | - | - |
| Dec 31, 2012 | 8.29M | 4.13M | 99.09% |
| Dec 31, 2011 | 4.16M | -1.18M | -22.10% |
| Dec 31, 2010 | 5.34M | 586.00K | 12.32% |
| Dec 31, 2009 | 4.76M | 5.63M | - |
| Dec 31, 2008 | -867.00K | -2.67M | - |
| Dec 31, 2007 | 1.80M | -2.95M | -62.15% |
| Dec 31, 2006 | 4.75M | 500.00K | 11.76% |
| Dec 31, 2005 | 4.25M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
EXAS News
- 10 days ago - Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect® MRD Test in Early Triple-Negative Breast Cancer at SABCS - Business Wire
- 20 days ago - Top 2 Health Care Stocks You May Want To Dump This Month - Benzinga
- 27 days ago - Exact Sciences Reinforces International Leadership in Breast Cancer with Strong Presence at 2025 San Antonio Breast Cancer Symposium - Business Wire
- 4 weeks ago - Exact Sciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Exact Sciences Corporation - EXAS - Business Wire
- 4 weeks ago - Why the Stock Price of This Cancer Screening Company Soared 17% Thursday - Investopedia
- 4 weeks ago - Exact Sciences Corporation (EXAS) M&A Call Transcript - Seeking Alpha
- 4 weeks ago - SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Exact Sciences Corporation (Nasdaq – EXAS) - GlobeNewsWire
- 4 weeks ago - Is it too late to buy Exact Sciences stock after Abbott's $21B deal? - Invezz